Piramal Pharma Limited vs Sun Pharmaceutical Industries Limited

A side-by-side comparison of Piramal Pharma Limited (PPLPHARMA) and Sun Pharmaceutical Industries Limited (SUNPHARMA) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.

The verdict

On the numbers, Sun Pharmaceutical Industries Limited leads PPLPHARMA vs SUNPHARMA on 11 of 14 metrics (1 undecided). See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).

  • Valuation22
  • Profitability04
  • Growth01
  • Size & financial health04
ValueReturnsMarginGrowthScaleLow debt

Each axis shows this group's split of that metric, scaled so the leader sits at the edge. Relative to each other, not an absolute score.

Valuation

Even

How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.

-90.00
P/E ratio
36.79
3.46
P/B ratio
5.35
0.07%
Dividend yield
0.86%
₹-2.46
EPS
₹47.80

Profitability

SUNPHARMA takes 4/4

How efficiently each company turns capital and sales into profit. Higher is better.

-3.99%
Return on equity
13.74%
1.21%
Return on capital
17.46%
10.39%
EBITDA margin
30.33%
-3.67%
Net margin
19.69%

Growth

SUNPHARMA takes 1/2

Three-year compounded growth. Faster-growing businesses can justify a higher valuation.

2.77%
Revenue CAGR (3Y)
10.03%
—
Profit CAGR (3Y) even
10.57%

Size & financial health

SUNPHARMA takes 4/4

Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.

₹26,307 Cr
Market cap
₹4.22L Cr
₹8,869 Cr
Revenue
₹58,462 Cr
₹-326 Cr
Net profit
₹11,509 Cr
0.67
Debt / equity
0.06
Piramal Pharma Limited
  • + []
  • − ["The company has delivered a poor sales growth of 7.0% over past five years.", "Company has a low return on equity of -0.9% over last 3 years.", "Company reported a net loss of ₹326 Cr in its latest financial year."]
Sun Pharmaceutical Industries Limited
  • + ["Company has delivered good profit growth of 38.3% CAGR over last 5 years", "Company has been maintaining a healthy dividend payout of 33.4%", "Company is almost debt free."]
  • − ["Stock is trading at 5.05 times its book value"]
Piramal Pharma Limited full analysis Sun Pharmaceutical Industries Limited full analysis

This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.